Cellectis RSI
What is the RSI of Cellectis?
The RSI of Cellectis is 55.61
What is the definition of RSI?
The relative strength index (RSI 14) is a momentum indicator that compares the magnitude of gains and losses over a specified time period to measure speed and change of price movements of a security.
14-day period
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI of companies in the Health Care sector on NASDAQ compared to Cellectis
What does Cellectis do?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Companies with rsi similar to Cellectis
- Laurion Mineral Exploration has RSI of 55.60
- Cymbria has RSI of 55.60
- Veto Switchgears and Cables has RSI of 55.60
- North American Nickel has RSI of 55.60
- Alimera Sciences has RSI of 55.60
- Redcape Hotel has RSI of 55.60
- Cellectis has RSI of 55.61
- American Pacific Borates has RSI of 55.62
- Interface has RSI of 55.62
- Paragon ID SA has RSI of 55.62
- WestRock has RSI of 55.62
- Facebank has RSI of 55.62
- Drax plc has RSI of 55.62